Ludovica Pizzetti has over 15 years of experience advising clients on both UK and EU competition law matters. Ludovica has a highly international profile: she is dual-qualified in the UK and Italy and is fluent in Italian, English, and French.
Ludovica’s experience in relation to behavioral matters includes advising clients on distribution agreements, licensing, competitor collaborations, pricing and discounting practices, parallel trade, pay for delay, product disparagement, no-poach, and other labor-related competition matters. Ludovica has also experience in assisting clients in the context of antitrust investigations and devising their response strategy, in advising clients in relation to leniency and other self-reporting mechanisms, as well as in devising tailored antitrust compliance programs and “dawn raids” training.
Ludovica has worked on several M&A transactions and regularly assists clients in relation to multijurisdictional deals, including advising on deal structure, overlap analysis, filing requirements, and antitrust risk assessment (including in relation to risk of Article 22 EUMR referrals). In this context, she has extensive experience in securing merger control and FDI clearances and coordinating the work of local counsel around the world.
Ludovica’s practice is largely focused on the life sciences and healthcare sector; her extensive experience in the pharma industry has been further enhanced in the context of a secondment at Novo Nordisk Ltd. Other sectors of expertise include telecoms, media, oil and gas, as well as fast-moving consumer goods.
Prior to joining the firm, Ludovica worked in the competition/antitrust group at a London magic circle law firm and has also undertaken a traineeship at the European Commission (DG Competition) as a blue book stagiaire.
Experience
- Honeywell International, Inc in its US$2.16 billion acquisition of Sundyne, LLC (UK and several other merger control and FDI filings).
- LigaChem Biosciences Inc in its US$25 million strategic investment in Iksuda Therapeutics (UK FDI filing).
- Novo Nordisk its US$11 billion acquisition of manufacturing sites belonging to Catalent, Inc. (EU, UK and several other merger control and FDI filings).
- Pfizer in its US$43 billion acquisition of Seagen Inc. (EU, UK and other merger control and FDI filings).
- AT&T in its US$43 billion sale of the WarnerMedia business to Discovery (EU, UK and several other merger control and FDI filings).
- Bristol-Myers Squibb in its US$4.1 billion acquisition of Turning Point Therapeutics.
- Pfizer in the spin-off of its Upjohn division to Mylan NV (EU and several other international filings).
- Penguin Random House in its US$2.17 billion acquisition of publishing house Simon & Schuster (UK and several other international filings).
- Boston Scientific in its $1.07 billion acquisition of Lumenis Ltd Surgical Business (UK and several other international filings).
- Boston Scientific in its $4.2 billion public takeover of BTG (UK and several other international filings).
- Monsanto in its $63 billion acquisition by Bayer (EU and several other international filings, including management of divestment process in the EU).
Perspectives
Recognition
Credentials
Education
- Postgraduate Diploma in Competition Law, King's College London, 2015
- Masters Degree in Law, Public and International Law, Università degli Studi di Siena, 2009
- LL.M., EU Law, Competition Law, University College London, 2007
Admissions
- England and Wales
- Milan Bar (Ordine Degli Avvocati Di Milano)
Languages
- Italian
- English
- French